Follow us on Twitter
This page is updated frequently with new Bowel-related patent applications. Subscribe to the Bowel RSS feed to automatically get the update: related Bowel RSS feeds. RSS updates for this page: Bowel RSS
|| List of recent Bowel-related patents
| 4-oxo-2-pentenoic acid and the health of the digestive tract|
The present invention relates generally to compositions with a health benefit. In particular, the invention relates to the field of inflammatory disorders of the digestive tract, for example, ileitis, colitis, rectal inflammation, pharyngitis, leaky gut syndrome, irritable bowel syndrome and inflammatory bowel disease.
| Methods for treating inflammatory diseases with compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof|
There are provided methods for treating an inflammatory diseases chosen from inflammatory bowel diseases, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, acute lung injury, bronchopulmonary dysplasia, cystic fibrosis, bronchitis, bronchiolitis, arthritis, osteoarthritis, ankylosing spondylitis and rheumatism. The method comprise administering to a subject in need thereof an effective amount of at least one lipid and an effective amount of at least one compound chosen from compounds of the present disclosure.
Scf Pharma Inc.
| Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders|
The invention provides novel guanylate cyclase-c agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cgmp-dependent phosphodiesterase.
Synergy Pharmaceuticals, Inc.
| Method, composition and package for bowel cleansing|
The present invention provides a highly palatable colon cleansing formulation that utilizes a low chloride electrolyte-replenishing base solution. When formulated with polyethylene glycol and a selected sugar alcohol, the formulation offers the advantages of superior palatability without undesirable concomitant side effects or a decrease in cleansing efficacy..
Braintree Laboratories, Inc.
| Controlled-release solid dosage forms of mesalamine|
Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-release solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets.
| Steroid sparing agents and methods of using same|
This invention relates generally to methods of treating inflammatory bowel diseases (ibd), asthma, crohn's disease (cd), multiple sclerosis (ms), rheumatoid arthritis (ra), graft versus host disease (gvhd), host versus graft disease, and various spondyloarthropathies, comprising administering a steroid-sparing effective amount of an immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions..
Biogen Idec Ma Inc.
|Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists|
This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes.
Abbvie Bahamas Limited
|Diagnostic agent and diagnostic irritable bowel syndrome induced by abnormal proliferation of enterobacteria|
[selected drawing] none. .
|Method for treatment of diarrhea-predominant irritable bowel syndrome|
The present invention provides methods for treating diarrhea-predominant irritable bowel syndrome comprising administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea-predominant irritable bowel syndrome (d-ibs). Treatment of d-ibs includes the treatment of the diarrhea component of d-ibs as well as the pain, abdominal discomfort and other symptoms associated with d-ibs.
|Liposomal corticosteroids for treatment of inflammatory disorders in humans|
The invention relates to a pharmaceutical composition comprising liposomes composed of non-charged vesicle-forming lipids, optionally including not more than 10 mole percent of negatively charged vesicle-forming lipids and/or not more than 10 mole percent of pegylated lipids, the liposomes having a selected mean particle diameter in the size range of 40-200 nm and comprising a first corticosteroid in water soluble form, for the site-specific treatment of inflammatory disorders in humans, providing in human patients a fast, strong, and durable anti-inflammatory effect for at least 2 weeks at a dose of at most 5 mg/kg body weight of prednisolone or an equipotent dose corticosteroid other than prednisolone at a treatment frequency of at most once per two weeks. Furthermore the present invention relates to the application of the above-mentioned pharmaceutical composition given as intervention therapy in inflammatory disorders such as rheumatic disease or a related inflammatory connective tissue disorder, inflammatory diseases of the kidney or inflammatory bowel disorders, in combination with chronic therapy with a second free corticosteroid formulation or in combination with chronic treatment with a disease-modifying agent such as methotrexate..
Enceladus Pharmaceuticals B.v.
Conjugate of polyethylene gylcol and naloxone and pharmaceutical composition and use thereof
Provided are a peg-naloxone conjugate of general formula (ii) and a pharmaceutical composition comprising the conjugate. In the conjugate, n is an integer in the range of 1-20.
Jenkem Technology Co., Ltd. (tianjin)
Sik inhibitor for use in a treating an inflammatory and/or immune disorder
The present invention relates to the discovery that salt inducible kinases (siks) suppress the formation of anti-inflammatory molecules such as il-10, which are important for the resolution of inflammation and identifies sik inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.. .
Dana-farber Cancer Institute, Inc.
Heterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Method for treating inflammation
A method for reducing or alleviating inflammation in a subject includes administering to the subject a therapeutically effective amount of: (a) ac-tmp-1 or a biologically active fragment or variant of ac-tmp-1; (b) ac-tmp-2 or a biologically active fragment or variant of ac-tmp-2; or (c) a combination of (a) and (b), to thereby reduce or alleviate inflammation in the subject. A method for preventing or treating asthma or inflammatory bowel disease in a subject includes administering to the subject a therapeutically effective amount of: (a) ac-tmp-1 or a biologically active fragment or variant of ac-tmp-1; (b) ac-tmp-2 or a biologically active fragment or variant of ac-tmp-2; or (c) a combination of (a) and (b), to thereby prevent or treat asthma or inflammatory bowel disease in the subject.
James Cook University
Mirna biomarkers for ulcerative colitis
Methods for diagnosing inflammatory bowel disease and ulcerative colitis using mirna biomarkers for these diseases are provided. Differential expression of the mirna biomarkers in blood fractions, e.g., platelets, of diseased individuals as compared to expression levels in normal individuals indicates the presence of ibd or ulcerative colitis.
Treatments for gastrointestinal disorders
The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including irritable bowel syndrome and constipation.. .
Ironwood Pharmaceuticals, Inc.
Tl1a model of inflammation fibrosis and autoimmunity
This invention relates transgenic animals that overexpress tl1a in a tissue specific manner to model inflammatory bowel disease (ibd), such as colitis, crohn's disease and ulcerative colitis, fibrosis, and related inflammatory diseases and conditions. Tl1a transgenic animals constitutively express both tl1a and gfp in lymphoid and myeloid cell lineages, allowing convenient identification and sorting of immune cells involved in ibd disease progression, such as t-cells, antigen presenting cells (apc), and dendritic cells (dc).
Cedars-sinai Medical Center
Formulation for treatment of irritable bowel disease
The present invention relates to an effective formulation for the treatment or the prevention of irritable bowel syndrome, a method for treating irritable bowel syndrome, and processes for preparing such formulations.. .
Aboca S.p.a. Societa' Agricola
Integral child training toilet
An integral training potty comprised of a child safety seat and waste collection apparatus, allowing a small child to evacuate his or her bowel or bladder. The waste collection apparatus being removable, without disturbing or removing the seated child.
An enema includes a liquid in a dispenser having a bottle, a nozzle attached to the bottle, and a valve. The valve may be a membrane having a slit and a thickness of at most 0.90 mm.
C.b. Fleet Company, Incorporated
Treatment of inflammatory bowel disease
Wherein x, y, b, r2, r3, r4, r5, r6 and n have the meanings found herein.. .
Method for treating intestinal diseases presenting at least one inflammatory component
The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (ibd) or diverticular disease using budesonide mmx compositions.. .
Cosmo Technologies Limited
Slowly fermentable soluble dietary fiber
The embodiments described herein provide a method for improving bowel health by increasing short chain fatty acid concentration in the colon of a mammal including administering to the mammal a composition having from about 0.1 grams to about 50 grams of a treated bran product. After administration, the treated bran product results in an increased short chain fatty acid production during fermentation in the colon as compared to untreated bran fermented in the colon..
Purdue Research Foundation
Method for prevention of colectomy
The present invention relates to methods of preventing or reducing the need of colectomy. In particular, the present invention relates to an oligonucleotide, for use in the treatment of an inflammatory bowel disease, such as ulcerative colitis (uc) or crohn's disease, in a subject that is refractory or responds insufficiently or is intolerant to anti-inflammatory therapy, wherein said oligonucleotide is repetitively administered as a single exposure..
Index Pharmaceuticals Ab
Self-stabilized encapsulated imaging system
Wireless capsule endoscope technology has been used to image portions of the gastrointestinal (gi) tract, particularly the small bowel. However in other gi organs, especially those having larger-lumens, the capsule may become destabilized and tumble, precluding meaningful interpretation of the acquired images.
Uti Limited Partnership
Treatment of th17 mediated inflammatory diseases
The present invention provides methods and means to reduce inflammation associated with irf-4, ap-1 and th17 mediated diseases. In particular, the invention provides methods and means to treat multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and psoriasis and related conditions..
Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention.
Meso Scale Technologies, Llc
Systems and methods for selectively stimulating components in, on, or near the pudendal nerve or its branches to achieve selectively physiological responses
Systems and methods selectively stimulate components of the pudendal nerve away from the sacral root to evoke desired physiologic responses in persona who lack the ability to otherwise produce these responses—e.g., maintain continence and/or produce micturition, and/or provide male/female sexuality responses, and/or provide bowel responses. The systems and methods use a multiple electrode array, or individual electrodes, placed on, in, or near the pudendal nerve.
Case Western Reserve University
The invention relates to compounds acting as selective antagonists of transient receptor potential cation channel subfamily m member 8 (trpm8), and having formula (i). Said compounds are useful in the treatment of diseases associated with activity of trpm8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exhacerbated respiratory disorders and urological disorders..
Azathioprine oral suspensions and methods of use
Compositions of azathioprine oral suspensions are disclosed. Disclosed azathioprine oral suspensions may be used to administer azathioprine to subjects such as children and geriatric patients that may have difficulty in swallowing solid dosage forms.
Professional Compounding Centers Of America
Novel triazinedione derivatives as gabab receptor modulators
The present invention provides novel compounds of formula i wherein w1, w2, w3, w4, w5, b, x1, x2, x3, x4, x5, e and l are as defined herein; invention compounds are gamma amino butyrique acid receptor-subtype b (“gabab”) positive allosteric modulators (enhancers), which are useful to provide methods of treating or preventing diseases or disorders, including treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, panic disorder, posttraumatic stress disorders, urge urinary incontinence, gastroesophageal reflux disease, transient lower oesophageal sphincter relaxations, functional gastrointestinal disorders and irritable bowel syndrome.. .
Addex Pharma S.a.
Popular terms: [SEARCH]
Bowel topics: Bowel Disease, Inflammatory Bowel Disease, Irritable Bowel Syndrome, Inflammation, Mercaptopurine, Probiotics, Abdominal Pain, Discomfort, Bowel Movement, Gastrointestinal, Ulcerative Colitis, Rheumatoid Arthritis, Jejunal Tube, Spring Mechanism, Small Bowel
Follow us on Twitter
This listing is a sample listing of patent applications related to Bowel for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bowel with additional patents listed. Browse our RSS directory or Search for other possible listings.